Dzekova-Vidimliski Pavlina, Asani A, Selim Gj, Gelev S, Polenakovic Momir, Sikole Aleksandar
University Clinic of Nephrology, Skopje, R. Macedonia.
Prilozi. 2008 Dec;29(2):201-11.
Clinical features, aminotransferases levels, and antibody to HCV have only limited correlation with the activity of liver disease and cannot accurately predict persistence versus eradication of the virus in haemodialysis patients. Although permanent loss of serum HCV RNA appears to correlate with resolution of the disease, little is known about the predictive value of a single HCV RNA value. The aim of the study was to evaluate the viraemia in the serum of HCV antibody positive haemodialysis patients during a period of 3 years. The study group consisted of 65 HCV antibody positive patients from our dialysis unit. HCV antibodies were measured every 6 months by ELISA third-generation assay. The presence of serum HCV RNA was assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) once a year during the period of 3 years. Serum levels of aminotransferases were measured monthly with standard automated analyzers. There were three different patterns of viraemia after the third assessment of the serum HCV RNA in HCV antibody positive patients: 47% (30/65) were persistently HCV RNA positive, 38% (25/65) were intermittently HCV RNA positive, and 15% (10/65) were persistently HCV RNA negative. The dominant genotype was 1a, detected in 97% of the patients positive for HCV RNA. The HCV RNA persistently positive patients had significantly higher levels of ALT compared to HCV RNA persistently negative patients (50.07 +/- 30.0 vs. 28.5 +/- 10.0 U/L, p < 0.027). There was no significant difference between the three groups of patients according to age, haemodialysis duration, and serum levels of AST. This pattern of intermittent viraemia clearly showed that a single negative result of the presence of serum HCV RNA in an HCV antibody positive patient should not be taken as a proof of a persistent resolution of HCV. Thus, repeated testing for HCV RNA is necessary to assess viraemia accurately in HCV antibody positive patients. HCV antibody positive patients who were persistently serum HCV RNA negative could be potentially infectious because of the possibility of the persistence of occult hepatitis C.
临床特征、氨基转移酶水平以及丙肝病毒抗体与肝病活动度的相关性有限,无法准确预测血液透析患者体内病毒的持续存在或清除情况。虽然血清丙肝病毒RNA的永久性消失似乎与疾病的缓解相关,但对于单个丙肝病毒RNA值的预测价值知之甚少。本研究的目的是评估丙肝病毒抗体阳性的血液透析患者在3年期间血清中的病毒血症情况。研究组由来自我们透析单元的65例丙肝病毒抗体阳性患者组成。每6个月通过第三代酶联免疫吸附试验检测丙肝病毒抗体。在3年期间,每年通过逆转录聚合酶链反应(RT-PCR)评估血清丙肝病毒RNA的存在情况。每月使用标准自动分析仪测量氨基转移酶的血清水平。在对丙肝病毒抗体阳性患者进行第三次血清丙肝病毒RNA评估后,出现了三种不同的病毒血症模式:47%(30/65)持续丙肝病毒RNA阳性,38%(25/65)间歇性丙肝病毒RNA阳性,15%(10/65)持续丙肝病毒RNA阴性。主要基因型为1a型,在97%的丙肝病毒RNA阳性患者中检测到。与持续丙肝病毒RNA阴性的患者相比,持续丙肝病毒RNA阳性的患者谷丙转氨酶水平显著更高(50.07±30.0 vs. 28.5±10.0 U/L,p<0.027)。根据年龄、血液透析时长和谷草转氨酶血清水平,三组患者之间无显著差异。这种间歇性病毒血症模式清楚地表明,丙肝病毒抗体阳性患者血清丙肝病毒RNA单次检测结果为阴性不应被视为丙肝持续清除的证据。因此,有必要对丙肝病毒RNA进行重复检测,以准确评估丙肝病毒抗体阳性患者的病毒血症情况。持续血清丙肝病毒RNA阴性的丙肝病毒抗体阳性患者可能具有潜在传染性,因为存在隐匿性丙型肝炎持续存在的可能性。